




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Homozygous Familial Hypercholesterolemia</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=a91761fa-5431-434b-b7d3-9c8977ea5d76</link>
        <description>Clinical Topic Feed: Homozygous Familial Hypercholesterolemia</description>
        <language>en</language>

        

                <item>
                    <title>JACC in a Flash | Electronic Alerts For Managing AS, MR; More</title>
<link>/Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1777637400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Asia 2026: Sex-Specific Differences in CVD Risk Factors in South Korea</title>
<link>/Latest-in-Cardiology/Articles/2026/04/15/17/13/Sex-Specific-Differences-in-CVD-Risk-Factors-in-South-Korea</link>                    <description>In adults with cardiovascular disease in South Korea, the rates of awareness and treatment of key cardiovascular risk factors were higher in women than in men, but they had lower rates of risk factor control, particularly for hypertension and hypercholesterolemia...</description>
                    <pubdate>1776367320000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>CORALreef AddOn: Novel PCSK9 Inhibitor Reduces LDL-C in Patients Not Meeting Goals</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/mon-1045am-coralreef-acc-2026</link>                    <description>The novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults already being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to results from the CORALreef AddOn trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC.</description>
                    <pubdate>1774885560000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Scientific Statement Highlights Emerging Role of Gene Editing in CV Care</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/03/24/18/20/ACC-Scientific-Statement-Highlights-Emerging-Role-of-Gene-Editing</link>                    <description>A new ACC Scientific Statement outlines the rapidly evolving landscape of gene-editing therapies and their growing relevance to cardiovascular disease, offering clinicians an overview of both the promise and the challenges of this transformative technology.</description>
                    <pubdate>1774536660000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Anti-ANGPTL3 Antibody Effective, Safe For Targeting LDL-C in HoFH</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/01/20/18/24/Anti-ANGPTL3-Antibody</link>                    <description>SHR-1918, a fully human monoclonal antibody targeting angiopoietinlike 3 (ANGPTL3), was associated with a manageable safety profile and substantial reduction in LDL-C in patients with homozygous familiar hypercholesterolemia (HoFH) already taking stable lipid-lowering therapy...</description>
                    <pubdate>1768998600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Improving The Culture and Climate Surrounding Cardiology</title>
<link>/Latest-in-Cardiology/Articles/2025/11/25/17/05/eagles-eye-view-03dec2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension.</description>
                    <pubdate>1764769080000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>New Studies Reveal Rising Rates of HF and High Blood Pressure</title>
<link>/Latest-in-Cardiology/Journal-Scans/2025/11/26/14/25/New-Studies-Reveal-Rising-Rates-of-HF-and-HBP</link>                    <description>The prevalence of heart failure (HF) and hypertension, respectively, are on the rise among U.S. adults, according to two separate studies published in JACC that use data from the National Health and Nutrition Examination Survey (NHANES).</description>
                    <pubdate>1764170460000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Journals Publish Latest Science From AHA 2025</title>
<link>/Latest-in-Cardiology/Articles/2025/11/06/13/19/JACC-Journals-Publish-Latest-Science-From-aha-2025</link>                    <description>AHA 2025 features key science simultaneously published across ACC&#39;s JACC Journals, including JACC, JACC: CardioOncology, JACC: Advances, JACC: Case Reports, JACC: Heart Failure and JACC: Cardiovascular Imaging.</description>
                    <pubdate>1762527600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Middle East 2025: CVD Risk Increases the Longer Immigrants Live in the US</title>
<link>/Latest-in-Cardiology/Articles/2025/10/01/18/04/CVD Risk</link>                    <description>New immigrants to the U.S. have a lower prevalence of cardiovascular disease risk factors than individuals born in the U.S., but these risk factors increase the longer they live in the U.S., a so-called &quot;healthy immigrant effect,&quot; according to research presented during the ACC Middle East 2025 Together with 16th Emirates Cardiac Society Conference, held in Dubai, UAE.</description>
                    <pubdate>1759414560000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Emerging Gene Therapies For Familial Hypercholesterolemia</title>
<link>/Latest-in-Cardiology/Articles/2025/05/27/10/55/Emerging-Gene-Therapies-For-Familial-Hypercholesterolemia</link>                    <description>Given advancements in the understanding of the genetic underpinnings of several cardiovascular diseases (CVDs), there is an increased focus on the use of targeted gene therapies in the treatment of some of these conditions.</description>
                    <pubdate>1748362620000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>